Knee Arthroscopic SurgeryNCT07838480
Ultrasound Guided Femoral Nerve Block Versus Adductor Canal Block by Using Bupivacaine and Magnesium Sulphate for Post-Operative Analgesia
A study testing Group II: Ultrasound Guided Femoral Nerve Block and group III : Adductor Canal Block group in people with Knee Arthroscopic Surgery and Analgesia, run by Tanta University at 1 site in Egypt.
Trial summary
Ultrasound Guided Femoral Nerve Block versus Adductor Canal Block by Using Bupivacaine and Magnesium Sulphate Read more about this study
- Who is it for?
- Ages 21 to 60 years
- Conditions the study is for
- Knee Arthroscopic Surgery, Analgesia, Femoral Nerve Block (FNB)
- What is being tested?
- Group II: Ultrasound Guided Femoral Nerve Block and group III : Adductor Canal Block group
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Nov 2024to 30 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age 21-60 years,
- both sexes, American Society of Anesthesiologists classification I-II and - -patients scheduled for elective Knee arthroscopic surgeries under spinal anesthesia.
Who cannot join
- Patient refusal.
- Patients on chronic pain medications or have a history of substance abuse.
- Patients who are unable to describe their postoperative pain (neuropsychiatric disorder).
- Patients with a history of coagulopathy.
- Patient with morbid obesity (body mass index ≥40 kg/m2).
- Patients with known local anesthetics and opioid allergy.
Show all 9Show fewer
- Patients with infection at the site of the needle puncture.
- Patients with major respiratory, cardiac, renal or hepatic disorders.
- Patients on calcium channel blockers.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Ultrasound Guided Femoral Nerve Block Versus Adductor Canal Block by Using Bupivacaine and Magnesium Sulphate for Post-Operative Analgesia After Knee Arthroscopic Surgeries
Ultrasound Guided Femoral Nerve Block versus Adductor Canal Block by Using Bupivacaine and Magnesium Sulphate
Read the detailed description
Ultrasound Guided Femoral Nerve Block versus Adductor Canal Block by Using Bupivacaine and Magnesium Sulphate for Post-Operative Analgesia after knee Arthroscopic Surgeries: A Randomized Controlled Study
- Being tested
- Group I: control group, Group II: Ultrasound Guided Femoral Nerve Block, group III : Adductor Canal Block group
- Keywords
- Femoral Nerve Block, Adductor Canal Block, Post-Operative Analgesia, knee Arthroscopic Surgeries
- Medical subject headings
- Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group I: control groupProcedure or surgery
Group I: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), with no intervention as a control group.
Group II: Ultrasound Guided Femoral Nerve BlockProcedure or surgery
Group II: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided FNB will be performed at the end of surgery, with 20 ml of 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml.
group III : Adductor Canal Block groupProcedure or surgery
Group III: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided ACB will be performed at the end of surgery, with 20 ml 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml.
| Study group | Role | What they receive |
|---|---|---|
| Group I: control group | Placebo comparator | Group I: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), with no intervention as a control group. Receives: Procedure: Group I: control group |
| Group II: Ultrasound Guided Femoral Nerve Block | Experimental | Group II: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided FNB will be performed at the end of surgery, with 20 ml of 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml. Receives: Procedure: Group II: Ultrasound Guided Femoral Nerve Block |
| Group III : Adductor Canal Block group | Experimental | Group III: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided ACB will be performed at the end of surgery, with 20 ml 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml. Receives: Procedure: group III : Adductor Canal Block group |
What is being measured
The primary outcome is the main question the study is designed to answer.
The total post-operative morphine consumption
Measured: 24 hours postoperatively
Secondary outcomes (1)
Assessment of pain by Numeric Rating Scale
Measured: Immediately after discharge to the PACU and ward at 1hour, 3hour, 6hour, 12hour, 24 hours.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2026
- Study start30 Nov 2024
- Primary completion30 Nov 2025
- Study completion30 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Knee Arthroscopic SurgeryStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nourhan Aladdin Ali Khidr, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07838480
- Sponsor's protocol ID
- 36265MS728/11/24
- Status last verified
- Nov 2024
- First submitted
- 10 Sep 2026
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: It will be available if it needed
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasound Guided Femoral Nerve Block Versus Adductor Canal Block by Using Bupivacaine and Magnesium Sulphate for Post-Operative Analgesia After Knee Arthroscopic Surgeries
- ClinicalTrials.gov ID
- NCT07838480
- Acronym / sponsor ID
- 36265MS728/11/24
- Keywords
- Femoral Nerve Block, Adductor Canal Block, Post-Operative Analgesia, knee Arthroscopic Surgeries
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 30 Nov 2024 (actual)
- Primary completion
- 30 Nov 2025 (actual)
- Study completion
- 30 Nov 2025 (actual)
- First posted
- 24 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Ultrasound Guided Femoral Nerve Block versus Adductor Canal Block by Using Bupivacaine and Magnesium Sulphate
Detailed description
Ultrasound Guided Femoral Nerve Block versus Adductor Canal Block by Using Bupivacaine and Magnesium Sulphate for Post-Operative Analgesia after knee Arthroscopic Surgeries: A Randomized Controlled Study
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group I: control group | Placebo comparator | Procedure: Group I: control groupGroup I: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), with no intervention as a control group. |
| Group II: Ultrasound Guided Femoral Nerve Block | Experimental | Procedure: Group II: Ultrasound Guided Femoral Nerve BlockGroup II: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided FNB will be performed at the end of surgery, with 20 ml of 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml. |
| Group III : Adductor Canal Block group | Experimental | Procedure: group III : Adductor Canal Block groupGroup III: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided ACB will be performed at the end of surgery, with 20 ml 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml. |
Who may qualify
- Ages
- 21 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Age 21-60 years,
- both sexes, American Society of Anesthesiologists classification I-II and - -patients scheduled for elective Knee arthroscopic surgeries under spinal anesthesia.
Key exclusion criteria (9 listed)
- Patient refusal.
- Patients on chronic pain medications or have a history of substance abuse.
- Patients who are unable to describe their postoperative pain (neuropsychiatric disorder).
- Patients with a history of coagulopathy.
- Patient with morbid obesity (body mass index ≥40 kg/m2).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group I: control groupGroup I: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), with no intervention as a control group. | Procedure or surgery | Group I: control group |
| Group II: Ultrasound Guided Femoral Nerve BlockGroup II: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided FNB will be performed at the end of surgery, with 20 ml of 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml. | Procedure or surgery | Group II: Ultrasound Guided Femoral Nerve Block |
| group III : Adductor Canal Block groupGroup III: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided ACB will be performed at the end of surgery, with 20 ml 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml. | Procedure or surgery | Group III : Adductor Canal Block group |
Primary outcome
The total post-operative morphine consumption
Time frame: 24 hours postoperatively
1 secondary outcome
Assessment of pain by Numeric Rating Scale
Time frame: Immediately after discharge to the PACU and ward at 1hour, 3hour, 6hour, 12hour, 24 hours.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
- Individual participant dataSharing planned: Yes. It will be available if it needed
Related trials for Knee Arthroscopic Surgery
Recruiting
Blood Flow Restriction Training in Knee Arthropathy
Knee Arthroscopic Surgery, Arthrogenic Muscle Inhibition
Not yet recruiting
The Effect of White and Pink Noise in Patients Undergoing Total Hip and Knee Arthroplasty
Arthroplasty, Replacement, Knee, Hip, Postoperative Nausea and Vomiting
Recruiting
The Effect of Nutritional Education on Post-Arthroscopic Nutritional Status
Arthroscopic Surgery, Nutrition
Active, not recruitingPhase 3
Dronabinol After Arthroscopic Surgery
Knee Osteoarthritis, Knee Injuries
Active, not recruiting
Active Noise-Cancelling Headphones With Closed-Loop Communication During Arthroscopic ACL Reconstruction
Anterior Cruciate Ligament Rupture, Anterior Cruciate Ligament (ACL) Tear
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Group II: Ultrasound Guided Femoral Nerve Block and group III : Adductor Canal Block group in people with Knee Arthroscopic Surgery and Analgesia, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The total post-operative morphine consumption (time frame: 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.